Complete Genomics, the Mountain View, CA-based company with a new model for inexpensive gene sequencing, has filed a prospectus with the Securities and Exchange Commission to go public. The company hopes to raise as much as $86 million through an IPO that would be underwritten by UBS, Baird, Jefferies & Co., and Cowen & Co. Complete Genomics already has a couple of well-known investors in public biotech companies—OrbiMed Advisors and Essex Woodland Health Ventures—among its top stockholders, as well as some traditional venture backers who hope to cash out—San Diego-based Enterprise Partners Venture Capital, Kirkland, WA-based OVP Venture Partners, and Palo Alto, CA-based Prospect Venture Partners.
